Linzagolix (KLH-2109; OBE-2109; trade name Yselty) is a potent, non-peptide, orally bioactive gonadotrophin releasing hormone (GnRH) antagonist. It is under development for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.

纯度：≥98%

CAS：935283-04-8